--- schema_version: "secwatch.filing_event.v1" accession: "0001022079-22-000157" form_type: "8-K" ticker: "DGX" cik: "0001022079" company_name: "QUEST DIAGNOSTICS INC" filed_at: "2022-11-18T23:59:59+00:00" generated_at: "2026-06-21T15:35:24.015867+00:00" event_type: "leadership" sentiment: "neutral" materiality_score: 0.3 calibrated_materiality_score: 0.3 confidence: "high" source: SEC EDGAR --- # Quest Diagnostics appoints four executive officers to severance plan; amends by-laws ## Summary - Four executives appointed as executive officers and Schedule B participants in severance plan: Mark Delaney, Mark Gardner, Karthik Kuppusamy, Patrick Plewman (effective Nov 16, 2022). - Board amended by-laws on Nov 14, 2022 regarding director nominations, proxy solicitations, and compliance with Rule 14a-19. - Schedule B participants receive 1x salary + 1x bonus pre-CIC; 2x salary + bonus post-CIC, plus benefits. - By-law amendments are ministerial, clarifying, and conforming changes. ## SEC filing metadata - accession: 0001022079-22-000157 - form_type: 8-K - ticker: DGX - cik: 0001022079 - company_name: QUEST DIAGNOSTICS INC - filed_at: 2022-11-18T23:59:59+00:00 - event_type: leadership - sentiment: neutral - materiality_score: 0.3 - calibrated_materiality_score: 0.3 - confidence: high - sec_items: 5.02, 5.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/dgx-20221114.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001022079-22-000157 - JSON: https://secwatch.observer/filing/0001022079-22-000157.json - Plain text: https://secwatch.observer/filing/0001022079-22-000157.txt ## Key facts - Executive change Patrick T. Plewman was appointed as Senior Vice President for Diagnostic Services at QUEST DIAGNOSTICS INC. - Action: appointed - Role: Senior Vice President for Diagnostic Services source text: On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan"). evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm - Executive change Karthik Kuppusamy was appointed as Senior Vice President, Clinical Solutions at QUEST DIAGNOSTICS INC. - Action: appointed - Role: Senior Vice President, Clinical Solutions source text: On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan"). evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm - Executive change Mark E. Delaney was appointed as Senior Vice President and Chief Commercial Officer at QUEST DIAGNOSTICS INC. - Action: appointed - Role: Senior Vice President and Chief Commercial Officer source text: On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan"). evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm - Executive change Mark A. Gardner was appointed as Senior Vice President, Molecular Genomics and Oncology at QUEST DIAGNOSTICS INC. - Action: appointed - Role: Senior Vice President, Molecular Genomics and Oncology source text: On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan"). evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm - Governance Changes QUEST DIAGNOSTICS INC: Amended and restated By-Laws to revise Sections 1.05, 1.06 and 1.07 regarding director nominations and proxy solicitations, including compliance with Rule 14a-19, and incorporate ministerial, clarifying and conforming changes (effective 2022-11-14). - Change: bylaw amendment - Effective: 2022-11-14 source text: On November 14, 2022, the Board of Directors (the “Board”) of the Company amended and restated the Company's By-Laws (the "By-Laws"). The amendments (a) revise Sections 1.05, 1.06 and 1.07 with respect to nominations of directors and solicitations of proxies, including compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes. evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.